FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound based on dihydronaphthyridinone of formula (I), where A, B, R1-R6 are defined in the claims, and also relates to its pharmaceutically acceptable salt and stereoisomers. The compound has a selective inhibitory effect on RIPK1.
(I)
EFFECT: pharmaceutical composition containing a compound of formula (I) and its use in the preparation of a medicament for the treatment of diseases or conditions associated with RIPK1 are also provided.
16 cl, 3 tbl, 90 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2815814C1 |
| 1,2,4-TRIAZINE-3-AMINE DERIVATIVES | 2011 |
|
RU2771819C2 |
| TLR7 AGONISTS | 2019 |
|
RU2817014C2 |
| NITROIMIDAZOLE DERIVATIVE AGAINST PULMONARY TUBERCULOSIS | 2016 |
|
RU2675622C1 |
| FGFR INHIBITOR, METHOD FOR PRODUCTION AND APPLICATION THEREOF | 2019 |
|
RU2771526C1 |
| 6-5 CONDENSED RINGS AS C5a INHIBITORS | 2018 |
|
RU2780338C2 |
| BICYCLIC DERIVATIVES | 2019 |
|
RU2794894C2 |
| 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE, METHOD FOR ITS OBTAINING AND ITS APPLICATION | 2019 |
|
RU2804127C2 |
| PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2017 |
|
RU2796400C2 |
| HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | 2013 |
|
RU2671628C2 |
